The company, which has been operating in stealth mode for the past year, is focused on advancing its preclinical pipeline of gene therapies based on adeno-associated virus 9 (AAV9). The company is targeting diseases with significant unmet needs such as galactosemia, genetic causes of autism spectrum disorder, type 1 diabetes, and Bardet-Biedl syndrome (BBS).

AXV101, a candidate for BBS1, a subset of Bardet-Biedl syndrome, is being developed by Axovia Therapeutics, a majority-owned subsidiary of Jaguar Gene Therapy.

The new venture was created in collaboration with Deerfield Management, which funded the series A financing and helped establish academic collaborations for pipeline projects. Through Deerfield, Jaguar has access to an existing network of 18 key academic institutions.

Provention Bio's bispecific antibody boosts gene therapy safety in mice
Provention Bio has released results from a preclinical proof-of-concept study for its bispecific antibody-based molecule, PRV-3279, conducted in mouse...

AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...

Prevail Therapeutics granted gene therapy patent
The U.S. Patent and Trademark Office has issued a composition of matter patent (No. 10,837,028) to Prevail Therapeutics for its adeno-associated viral...

Taysha nabs rare pediatric disease, orphan drug status
Taysha Gene Therapies has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-104,...